GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » ROIC %

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) ROIC % : -109.47% (As of Sep. 2018)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Keryx Biopharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2018 was -109.47%.

As of today (2024-04-26), Keryx Biopharmaceuticals's WACC % is 0.00%. Keryx Biopharmaceuticals's ROIC % is -269.80% (calculated using TTM income statement data). Keryx Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Keryx Biopharmaceuticals ROIC % Historical Data

The historical data trend for Keryx Biopharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals ROIC % Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,091.91 -1,457.51 -292.98 -296.83 -452.33

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -388.49 -427.47 -265.18 -186.51 -109.47

Competitive Comparison of Keryx Biopharmaceuticals's ROIC %

For the Biotechnology subindustry, Keryx Biopharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's ROIC % falls into.



Keryx Biopharmaceuticals ROIC % Calculation

Keryx Biopharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2017 is calculated as:

ROIC % (A: Dec. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2016 ) + Invested Capital (A: Dec. 2017 ))/ count )
=-101.691 * ( 1 - 0.14% )/( (17.081 + 27.819)/ 2 )
=-101.5486326/22.45
=-452.33 %

where

Keryx Biopharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2018 is calculated as:

ROIC % (Q: Sep. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2018 ) + Invested Capital (Q: Sep. 2018 ))/ count )
=-58.744 * ( 1 - 0% )/( (47.54 + 59.787)/ 2 )
=-58.744/53.6635
=-109.47 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2018) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keryx Biopharmaceuticals  (NAS:KERX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Keryx Biopharmaceuticals's WACC % is 0.00%. Keryx Biopharmaceuticals's ROIC % is -269.80% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Keryx Biopharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Headlines

From GuruFocus

Baupost's Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals

By Holly LaFon Holly LaFon 05-12-2014

Klarman Gives Insight on Keryx Biopharmaceuticals Investment

By Bram de Haas Bram de Haas 01-26-2016